PAMELA MUNSTER, MD
Osteopathic Medicine at Usf Magnolia Dr, Tampa, FL
License number
Florida ME85618
Category
Osteopathic Medicine
Type
Medical Oncology
Address
Address
2
12902 Usf Magnolia Dr, Tampa, FL 33612
PO Box 917770, Orlando, FL 32891
PO Box 917770, Orlando, FL 32891
Phone
(813) 972-8413
(813) 979-7265 (Fax)
(813) 979-7265 (Fax)
Personal information
See more information about PAMELA MUNSTER at radaris.comName
Address
Phone
6539 Stonington Dr S, Tampa, FL 33647
Organization information
See more information about PAMELA MUNSTER at bizstanding.comPamela Munster MD
12902 Usf Magnolia Dr, Tampa, FL 33612
Industry:
Internist
Phone:
(813) 979-3980 (Phone)
Pamela Nathalie Munster
Professional information
Pamela Natalie Munster, Tampa FL
Specialties:
Oncologist
Address:
12902 Usf Magnolia Dr, Tampa, FL 33612
Education:
Doctor of Medicine*
Board certifications:
American Board of Internal Medicine Certification in Internal Medicine*, American Board of Internal Medicine Sub-certificate in Oncology (Internal Medicine)*
Pamela N Munster, Tampa FL
Specialties:
Internal Medicine, Medical Oncology, Hematology & Oncology, Hematology, General Practice, Gynecology
Work:
Moffitt Cancer Ctr
12902 Usf Magnolia Dr, Tampa, FL 33612 University of California at San Francisco
1600 Divisadero St, San Francisco, CA 94115
12902 Usf Magnolia Dr, Tampa, FL 33612 University of California at San Francisco
1600 Divisadero St, San Francisco, CA 94115
Education:
Universitat Bern (1989)
Methods For Enhancing The Efficacy Of Cytotoxic Agents Through The Use Of Hsp90 Inhibitors
US Patent:
2004011, Jun 10, 2004
Filed:
May 1, 2003
Appl. No.:
10/415878
Inventors:
Neal Rosen - New York NY, US
Pamela Munster - Tampa FL, US
Pamela Munster - Tampa FL, US
International Classification:
A61K038/00
US Classification:
514/002000
Abstract:
The administration of cytotoxic agents followed by the administration of heat shock protein 90 inhibitors, such as ansamycins, has a synergistic effect on the growth inhibition of cells. This synergy occurs at doses of each cytotoxic agent that normally only causes minimal growth inhibition of cells. Such combination therapy thus allows one to use lower doses of cytotoxic agents to avoid or reduce their respective toxicity to patients without compromising their growth inhibitory effects. Thus, these combinations can be used for the treatment of an animal, preferably a mammal, that has a cell proliferative disorder, whether the cells have wild-type Rb or are Rb deficient or Rb negative. One such method, directed to treating cell proliferative disorders includes the step of administering a therapeutic effective amount of a cytotoxic agent followed by administering a therapeutic effective amount of a heat shock protein 90 inhibitor. The cytotoxic agent may be a microtubule-affecting agent, topoisomerase II inhibitor, a platinum complex, paclitaxel, or a paclitaxel derivative. The HSP90 inhibitor may be an ansamycin, radicicol or a synthetic compound that binds to the ATP-binding site of HSP90.
Method Of Treatment For Cancers Associated With Elevated Her2 Levels
US Patent:
8518897, Aug 27, 2013
Filed:
Oct 22, 2010
Appl. No.:
12/910513
Inventors:
Neal Rosen - Englewood NJ, US
Pamela Munster - Tampa FL, US
Pamela Munster - Tampa FL, US
Assignee:
Sloan-Kettering Institute for Cancer Research - New York NY
International Classification:
C12Q 1/68
US Classification:
514 25, 435 61
Abstract:
Novel methods of treating proliferative disorders characterized by elevated Her-2, and the patient is then administered an effective amount of an HSP90 inhibitor.
Method Of Treatment For Cancers Associated With Elevated Her 2 Levels
US Patent:
7825094, Nov 2, 2010
Filed:
May 23, 2002
Appl. No.:
10/478023
Inventors:
Neal Rosen - Englewood NJ, US
Pamela Munster - Tampa FL, US
Pamela Munster - Tampa FL, US
Assignee:
Sloan-Kettering Institute for Cancer Research - New York NY
International Classification:
C12Q 1/68
US Classification:
514 25, 435 6
Abstract:
Novel methods of treating proliferative disorders characterized by elevated Her-2, and the patient is then administered an effective amount of an HSP90 inhibitor.